The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has provided Mindset Pharma with Scientific Advice on a range of points to finalise its MSP-1014 clicnial...
The clinical trial will be testing the safety and tolerability of MDMA-assisted therapy for patients living with treatment-resistant post-traumatic stress disorder (PTSD).
Algernon Pharmaceuticals has received approval to conduct a Phase 1 clinical study of an intravenous formulation (IVF) of DMT for the treatment of stroke in the...
Data from a collaborative study between the University Hospital Basel (UHB) and MindMed supports the clinical development of MindMed’s proprietary MM-120 product candidate – a pharmacologically...
Results from a small study suggest that low-dose ketamine could be an effective treatment for children living with ADNP syndrome, otherwise known as Helsmoortel-VanDerAa syndrome.
Heroic Hearts Project and Maya PBC are partnering to generate the largest structured dataset illustrating the health outcomes of psychedelic treatments for veterans and their family...
New study findings have shown that mice respond more to the antidepressant effects of the drug ketamine when administered by men and not by women.
A study by researchers at NYU Grossman School of Medicine has found that two doses of psilocybin reduced heavy drinking by 83 per cent when combined...
A new study by Johns Hopkins Medicine researchers compared psychedelic experiences with near-death experiences that were not drug-related, finding notable similarities in people’s attitudes toward death.
Biopharmaceutical company MindMed has dosed the first patient in its Phase 2b Trial of its pharmaceutically optimised form of LSD – MM-120 – in GAD.